ES8704005A1 - Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano. - Google Patents

Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.

Info

Publication number
ES8704005A1
ES8704005A1 ES526991A ES526991A ES8704005A1 ES 8704005 A1 ES8704005 A1 ES 8704005A1 ES 526991 A ES526991 A ES 526991A ES 526991 A ES526991 A ES 526991A ES 8704005 A1 ES8704005 A1 ES 8704005A1
Authority
ES
Spain
Prior art keywords
methods
oncogenic
detection
malignancy
assayed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES526991A
Other languages
English (en)
Other versions
ES526991A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of ES526991A0 publication Critical patent/ES526991A0/es
Publication of ES8704005A1 publication Critical patent/ES8704005A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

METODO PARA EVALUAR LA PROBABILIDAD DE MALIGNIDAD CELULAR EN UNA MUESTRA BIOLOGICA DE UN HOSPEDANTE HUMANO. COMPRENDE LAS OPERACIONES DE: PONER EN ESTRECHA ASOCIACION: A) UNA SONDA ESPECIFICA PARA UN PRODUCTO CELULAR, SIENDO ESTE PRODUCTO CELULAR MARN O SU PRODUCTO DE EXPRESION, EN DONDE EL MARN ES COMPLEMENTARIO A UNA SECUENCIA DE ADN DE UN RETROVIRUS CAPAZ DE TRANSFORMAR EN MALIGNA UNA CELULA NORMAL, DEL GRUPO QUE CONSISTE EN LOS ONCOGENES SRC, FPS, YES, FOS, MUY, ERC, MUY Y OTROS; Y B) UNA FUENTE DE MARN O SU PRODUCTO DE EXPRESION O PROCEDENTE DE CELULAS O FLUIDO FISIOLOGICO DE DICHO HOSPEDANTE HUMANO SOSPECHOSO DE CONTENER UN PRODUCTO CELULAR ASOCIADO A LA MALIGNIDAD CELULAR; Y DETERMINAR EL NIVEL DE UNION DE DICHA SONDA A DICHO PRODUCTO CELULAR COMO INDICATIVO DE LA PRESENCIA DE MALIGNIDAD CELULAR. TIENE APLICACION EN LA DIAGNOSIS DE CELULAS MALIGNAS, ASI COMO EN EL TRATAMIENTO DE LAS MISMAS.
ES526991A 1982-11-04 1983-11-03 Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano. Expired ES8704005A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43925282A 1982-11-04 1982-11-04
US49602783A 1983-05-19 1983-05-19

Publications (2)

Publication Number Publication Date
ES526991A0 ES526991A0 (es) 1987-03-01
ES8704005A1 true ES8704005A1 (es) 1987-03-01

Family

ID=27031979

Family Applications (2)

Application Number Title Priority Date Filing Date
ES526991A Expired ES8704005A1 (es) 1982-11-04 1983-11-03 Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
ES533105A Expired ES8600215A1 (es) 1982-11-04 1984-06-04 Un procedimiento para preparar un oligopeptidos antigenico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES533105A Expired ES8600215A1 (es) 1982-11-04 1984-06-04 Un procedimiento para preparar un oligopeptidos antigenico

Country Status (16)

Country Link
EP (1) EP0108564B1 (es)
JP (3) JPH0728759B2 (es)
AU (1) AU559912B2 (es)
BR (1) BR8306175A (es)
CA (1) CA1252046A (es)
DE (1) DE3376507D1 (es)
DK (1) DK498083A (es)
ES (2) ES8704005A1 (es)
FI (1) FI79411B (es)
GR (1) GR78948B (es)
IE (1) IE56509B1 (es)
IL (1) IL70067A (es)
NO (1) NO163986C (es)
NZ (1) NZ206096A (es)
PH (1) PH20994A (es)
PT (1) PT77605B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US6713619B1 (en) 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
ZA84617B (en) * 1983-02-14 1984-09-26 Arup Sen Synthetic polypeptides from viryl oncogenes
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
EP0177814A3 (en) * 1984-09-19 1987-12-02 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
IL76997A0 (en) * 1984-11-14 1986-04-29 Oncogene Science Inc Probes and methods useful for detecting chromosomal translocation
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US6200764B1 (en) 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
CA1296660C (en) * 1985-01-29 1992-03-03 Walter P. Carney Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5028527A (en) * 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
JP2648303B2 (ja) * 1985-04-04 1997-08-27 ジョージタウン・ユニバーシティ 型特異的乳頭腫ウイルスｄｎａ配列およびペプチド
EP0203587A3 (en) * 1985-05-30 1989-08-09 F. Hoffmann-La Roche Ag Ras oncogene peptides and antibodies
EP0206065A3 (en) * 1985-06-27 1989-04-19 James R. Feramisco Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids
US6083709A (en) * 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
AU615876B2 (en) * 1985-08-21 1991-10-17 Oncogene Science, Inc. Immunoassay for the detection of Oncogene encoded products
FR2594833B1 (fr) * 1986-02-26 1989-04-28 Centre Nat Rech Scient Proteines homologues de celles codees par des oncogenes humains, procede d'obtention de ces proteines et leurs applications immunologiques, physiopathologiques et therapeutiques
FI76119C (fi) * 1986-02-27 1988-09-09 Orion Yhtymae Oy Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
JPS6374492A (ja) * 1986-09-18 1988-04-04 Hiroshi Shiyuku モノクロ−ナル抗体
NO881560L (no) * 1987-05-05 1988-11-07 Hope City Fremgangsmaate for detektering av begynnende resistens motterapeutiske midler i kreftpasienter.
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
EP0304845A3 (en) * 1987-08-28 1991-03-06 Profile Diagnostic Sciences Inc. Method and kit for assaying gene expressions
CA1341191C (en) * 1988-04-18 2001-02-27 Robert Allan Weinberg Detection of neu gene expression and products
WO1989010375A1 (en) * 1988-04-22 1989-11-02 E.I. Du Pont De Nemours And Company Monoclonal antibodies specific for the harvey, kirsten and n ras proteins and their use as diagnostic reagents
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
ATE160877T1 (de) * 1988-08-12 1997-12-15 Ligand Pharm Inc Polypeptid-induzierte monoklonale rezeptoren gegen proteinliganden
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US7774144B2 (en) 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
KR100906102B1 (ko) 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7420028B2 (en) 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7452963B2 (en) 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
ATE529535T1 (de) 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
EP1570080A4 (en) 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2314378T3 (es) 2003-02-20 2009-03-16 Genomic Health, Inc. Uso de arn intronico para medir la expresion genica.
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
EP1641810B2 (en) 2003-06-24 2017-04-19 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
DK1644858T3 (da) 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
WO2005064019A2 (en) 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
ITPD20040065A1 (it) * 2004-03-15 2004-06-15 Univ Padova Peptidi della vitronectina e loro impiego terapeutico nella adesione degli osteoblasti
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
HUE051605T2 (hu) 2004-11-05 2021-03-01 Nsabp Found Inc Kemoterápiára adott válasz elõrejelzése génexpressziós markereket alkalmazva
US7622251B2 (en) 2004-11-05 2009-11-24 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
WO2008140557A2 (en) 2006-10-24 2008-11-20 Samuel Bogoch A method of predicting influenza outbreaks
AU2008266702A1 (en) 2007-05-30 2008-12-24 Elenore S. Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
WO2012162628A2 (en) 2011-05-25 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of ras oncoproteins
EP2734226A2 (en) 2011-07-20 2014-05-28 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
KR101973381B1 (ko) 2016-09-09 2019-04-29 드 노라 페르멜렉 가부시키가이샤 알칼리 수전해용 양극의 제조 방법 및 알칼리 수전해용 양극

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598686A (en) * 1977-04-29 1981-09-23 Dia Prosim Enzymes immobilised on a resin via chelation with a metal
IT1207172B (it) * 1979-02-15 1989-05-17 Anic Spa Processo per la preparazione dicorpi microporosi inglobanti uno o piu' agenti attivi.
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
PT77605A (en) 1983-12-01
GR78948B (es) 1984-10-02
DE3376507D1 (en) 1988-06-09
EP0108564B1 (en) 1988-05-04
JPH0728759B2 (ja) 1995-04-05
IL70067A (en) 1989-08-15
EP0108564A1 (en) 1984-05-16
CA1252046A (en) 1989-04-04
JPS59113898A (ja) 1984-06-30
JPH07215995A (ja) 1995-08-15
BR8306175A (pt) 1984-06-12
FI833952A (fi) 1984-05-05
ES533105A0 (es) 1985-10-01
JP2716670B2 (ja) 1998-02-18
ES526991A0 (es) 1987-03-01
JPH05328965A (ja) 1993-12-14
IE832493L (en) 1984-05-04
NO163986B (no) 1990-05-07
AU2065083A (en) 1984-05-10
AU559912B2 (en) 1987-03-26
DK498083A (da) 1984-05-05
ES8600215A1 (es) 1985-10-01
FI833952A0 (fi) 1983-10-28
PT77605B (en) 1986-05-05
FI79411B (fi) 1989-08-31
DK498083D0 (da) 1983-10-31
IL70067A0 (en) 1984-01-31
JPH0759188B2 (ja) 1995-06-28
IE56509B1 (en) 1991-08-28
NZ206096A (en) 1986-09-10
NO163986C (no) 1990-08-15
NO834014L (no) 1984-05-07
PH20994A (en) 1987-06-18

Similar Documents

Publication Publication Date Title
ES8704005A1 (es) Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
AU5535980A (en) Agent for leukocyte detection
IL57348A (en) Compositions and method for cancer detection
AU1319483A (en) Blood processing system for cell washing
IL59621A0 (en) Compositions,method and apparatus for the determination of blood gases and blood ph
ZA803732B (en) Detection of certain minerals of uraniu, zin, lead and other metals using photoluminescence
ES8205231A1 (es) Procedimiento para preparar complejos de platino (iv)-diami-na
EP0102381A4 (en) METHOD FOR IDENTIFYING AND CLEANING ANTIGENS (hLTAA) ASSOCIATED WITH HUMAN LUNG TUMOR AND CLINICALLY DETECTING AND DETERMINING THIS ANTIGENS.
GB2203831B (en) Apparatus and method for the diagnosis of malignant tumours
AU559983B2 (en) Platinum complexes, treatment of cancer
EP0301600A3 (en) Method for detection of the presence of undesired microorganisms
IL62615A0 (en) Organic complex of platinum,its preparation and its use for treating malignant tumours
BE896779A (fr) Ether de diglycidyle du dimethanolcyclohexane et ses produits de reaction.
EP2366712A3 (en) A tumor suppressor designated TS10Q23.3
DE3175634D1 (en) Process for detecting the presence of malignant and pre-malignant cells in humans
WO1990008457A3 (en) Method of detecting small cell carcinoma and use of acyl-peptide hydrolase and coding sequences therefor
BG39335A1 (en) Device for processing blood outside the organism
GB1534238A (en) Composition for treating leukemia and ascites tumour
ZA785906B (en) Process for improving the processing properties of powdery polyolefins
AU9120398A (en) A tumor suppressor designated ts10q23.3
DE2967534D1 (en) Product for detecting the presence of cancerous or malignant tumor cells
AU2253688A (en) Methods for breast cancer detection
ZA92264B (en) Prescreening of prostate cancer by serum prostatic specific antigen.
AU5921080A (en) Analyzing gold-bearing minerals
GB8510892D0 (en) Products for treating cancer

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20061125